AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Aspen to market AstraZeneca’s 7 anaesthetic medicines outside US
Posted on10 Jun 2016
Comments0
AstraZeneca has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global... Read More